Topline: In the Phase 3 VALIANT trial for C3 glomerulopathy and primary IC-MPGN, pegcetacoplan cut proteinuria by 68% versus placebo at Week 26 (p<0.0001), stabilized kidney function with a +6.3 mL/min/1.73 m2 eGFR difference (nominal p=0.03), and cleared C3 deposits on biopsy in the majority of treated patients, with 71% achieving zero C3 staining intensity (nominal p<0.0001). The core development is publication of the VALIANT pivotal results in The New England Journal of Medicine following U.S. approval of pegcetacoplan in July for patients 12 and older to reduce proteinuria in C3G and primary IC-MPGN. The study, the largest to date in these rare renal populations, enrolled 124 adolescent and adult patients, including post-transplant recurrence, and used twice-weekly subcutaneous dosing over a 26-week double-blind period before an open-label extension. NEJM visibility lands as Apellis and partner Sobi await a CHMP opinion in Europe before year-end, positioning the data squarely in front of regulators, HTA bodies, and guideline committees. Strategically, Apellis is extending its complement franchise upstream at C3 into nephrology and consolidating first-mover advantage with both regulatory approval and a high-profile peer-reviewed readout. The choice of a multi-pronged endpoint package—proteinuria, eGFR slope preservation over 26 weeks, and histopathologic C3 clearance—signals an intent to shape the evidentiary bar for future entrants. In a category where off-label C5 inhibition and emerging alternative pathway blockers have produced mixed renal signals, demonstrable histologic improvement alongside proteinuria reduction gives Apellis a differentiated narrative that can resonate with both regulators and payers. The timing also serves a market-education function: publication post-approval can accelerate prescriber confidence and support rapid inclusion in specialty center protocols ahead of European launch. For sites and CROs, VALIANT underscores two operational themes. First, complement programs in nephrology demand infrastructure for vaccination oversight, infection vigilance, and subcutaneous infusion support—capabilities concentrated in tertiary and transplant centers. Second, the incorporation of serial kidney biopsies and centralized immunofluorescence readouts in a global rare-disease study shows that histology can be executed at scale, but it concentrates enrollment at higher-expertise sites and elevates start-up and logistics complexity. Transplant programs may see immediate implications given inclusion of recurrent C3G, and pathology partners should anticipate expanded demand for standardized C3 scoring. For sponsors, the trial’s endpoint architecture will influence protocol design, pushing beyond single surrogate reliance and raising expectations for coherence across proteinuria, function, and tissue markers. For payers and HTA agencies, the combination of surrogate and histologic effects will be weighed against durability and hard renal outcomes, and against the care delivery burden of twice-weekly administration. Looking ahead, the near-term watch items are the CHMP opinion and how European HTAs value proteinuria and histology relative to time to ESKD. One-year data presented at ERA and ASN suggest persistence, but definitive readouts on sustained eGFR decline and transplant outcomes will drive guideline positioning and coverage depth. Competitive pressure will come from oral alternative-pathway inhibitors seeking convenience advantages; head-to-heads are unlikely, so cross-trial comparisons will shape uptake. Operationally, scaling treatment will hinge on complement-ready centers, REMS-aligned workflows, and patient support for home-based subcutaneous infusion. If Apellis can convert NEJM validation into rapid site onboarding and payer alignment, pegcetacoplan could set the reference standard for C3G and primary IC-MPGN, while the field tests whether composite renal endpoints with histology become the default for rare complement-mediated kidney diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
